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ABSTRACT 
Background & Aims: Eosinophilic esophagitis (EoE) is assessed endoscopically 
(endoscopic activity), based on grades of edema, rings, exudates, furrows, and strictures 
(EREFS). We examined variations in endoscopic assessments of severity, developed and 
validated 3 EREFS-based scoring systems, and assessed responsiveness of these systems 
using data from a randomized placebo-controlled trial of patients with EoE. 
Methods: For the development set, 5 gastroenterologists reviewed EREFS findings from 
266 adults with EoE and provided endoscopist global assessment scores (EndoGA, scale of 
0 to 10); variation (∆EndoGA) was assessed using linear regression. We evaluated simple 
scores (features given arbitrary values from 0 to 3) and developed 2 scoring systems 
(adjusted score range, 0–100). We then fitted our linear regression model with mean 
EndoGA to data from 146 adults recruited in centers in Switzerland and the United States 
between April 2011 and December 2012. For the validation set, we collected data from 120 
separate adults (recruited in centers in Switzerland and the United States between May 
2013 and July 2014), assessing regression coefficient-based scores using Bland-Altman 
method. We assessed the responsiveness of our scoring systems using data from a 
randomized trial of patients with EoE given fluticasone (n=16) or placebo (n=8). 
Results:  The distribution of EndoGA values differed among endoscopists (mean ∆EndoGA, 
2.6±1.8; range 0–6.6). We developed 2 regression-based scoring systems to assess overall 
and proximal and distal esophageal findings; variation in endoscopic features accounted for 
more than 90% of the mean EndoGA variation. In the validation group, differences between 
mean EndoGA and regression-based scores were small (ranging from –4.70 to 2.03), 
indicating good agreement. In analyses of data from the randomized trial, the baseline to 
end of study change in patients given fluticasone was a reduction of 24.3 in simple score 
(reduction of 4.6 in patients given placebo, P=.052); a reduction of 23.5 in regression-based 
overall score (reduction of 6.56 in patients given placebo, P=.12), and a reduction of 23.8 
(reduction of 8.44 in patients given placebo, P=.11). 
Conclusion: Assessments of endoscopic activity in patients with EoE vary among 
endoscopists. In an analysis of data from a randomized controlled trial, we found that newly 
developed scoring systems are no better than simple scoring system in detecting changes in 
endoscopic activity. These results support the use of a simple scoring system in evaluation 
of endoscopic activity in patients with EoE. clinicaltrials.gov no: NCT00939263 and NCT 
01386112 
Word count:  387. 
KEY WORDS: index, esophagus, variability in endoscopic assessment; instrument 
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INTRODUCTION 
Eosinophilic esophagitis (EoE) is defined as “a chronic, immune/antigen-mediated, 
esophageal disease characterized clinically by symptoms related to esophageal dysfunction 
and histologically by eosinophil-predominant inflammation”.1,2,3 
     As dysphagia is the most frequent complaint of adult EoE patients, 
esophagogastroduodenoscopy (EGD) represents an important diagnostic procedure.1,2,3 
Although endoscopic abnormalities are not pathognomonic of EoE, these are frequently 
assessed to aid in clinical decision making and interpretation of results of clinical trials and 
observational studies. In 2013, Hirano et al. described a classification and grading system of 
the following EoE-associated endoscopic alterations: edema, rings, exudates, furrows, and 
stricture(s) (EREFS).4 While no score to assess the overall endoscopic activity was 
developed, attempts have been made to use the EREFS system as a basis for a simple 
score, which is calculated by summing together the arbitrary values from zero to three based 
on presence and severity of various EoE-associated features.5,6 Dellon et al. reported that 
giving more weight to inflammatory features, such as exudates and edema, renders the 
EREFS-based score more responsive to anti-inflammatory treatment.7 These studies 
revealed differences in the way gastroenterologists synthesize information about the severity 
of individual features when assessing overall endoscopic severity, and emphasize the 
importance of methodologic considerations in developing an endoscopic score. 
     Therefore, we used data from the adult EoE activity index (EEsAI) study population to 
explore the variation in gastroenterologists’ assessment of endoscopic severity, used this 
information to develop and validate three EREFS-based scores, and assessed 
responsiveness of these scores using the data from randomized placebo-controlled clinical 
trial of fluticasone.8 
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PATIENTS AND METHODS 
Study population  
EEsAI study (clinicaltrials.gov ID:NCT00939263) was approved by local institutional review 
boards. The patient inclusion and exclusion criteria were previously published.9 
Assessment of endoscopic findings 
Distal and proximal esophageal sections were defined as those spanning 5 cm above the 
gastroesophageal junction and the top ½, respectively. Patients underwent EGD, during 
which endoscopic findings were assessed using EREFS system with modifications for 
stricture definitions (Supplementary Table 1 ).4 The endoscopists performing EGD also 
provided the overall severity grading (absent, mild, moderate, severe). 
     Five endoscopists (AS, AMS, ESD, IH, YR, who performed ≥200 EGDs in EoE patients), 
were provided a datasheet containing the grading of inflammatory (white exudates, furrows, 
edema) and fibrotic (rings, strictures, crêpe-paper) features. The experts provided an 
Endoscopist Global Assessment (EndoGA) ranging 0-10 (0, inactive EoE; 10, most active 
EoE) as an overall impression of endoscopic severity. 
Data handling and statistical analysis  
Data were double-entered into EpiData (version 3.1) and imported into Stata (version 13.1) 
or R Project for analyses. Results are presented as percentages for categorical variables or 
median (interquartile range [IQR]) for continuous variables. The most severe category for a 
given feature found in either esophageal section represented ‘overall’ severity. If data on 
feature’s severity in one esophageal section were missing, then that feature’s severity in 
another section represented ‘overall’ severity. 
Relationship between severity grading and EndoGA 
We analyzed the relationship between EndoGA (outcome) and overall severity grading (fixed 
effect) using linear mixed-effects regression. We examined box plots of mean EndoGA for 
EGD performed in one’s own center (EndoGAown), in another center (EndoGAothers), and 
mean difference between EndoGAown and EndoGAothers versus overall severity grading. We 
could not verify if physician 3 performed his/her patients’ EGDs and dropped observations 
from that center for this analysis. 
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Variation in expert assessment of endoscopic severi ty 
We examined the variation in the way endoscopists assessed overall endoscopic severity 
using several approaches. 1) The probability distributions of all EndoGA values provided by 
each expert were visualized using violin plots and boxplots. 2) To examine the per-patient 
variation, we calculated the difference between highest and lowest EndoGA values 
(∆EndoGA) from among five values assigned to findings of single EGD. A large ∆EndoGA 
value reflects disagreement in assessing that patient’s endoscopic severity. To examine 
which features contributed most to per-patient variation, ∆EndoGA was regressed on each 
feature, and the coefficient of determination (R2) was calculated. Features with a higher R2 
are more strongly associated with ∆EndoGA variance. A multivariable regression model with 
∆EndoGA as outcome and all the features as predictors was used to examine each feature’s 
contribution to variation in ∆EndoGA adjusted for all other features. 3) To assess the per-
feature variation, we fitted a multivariable regression model to each expert’s EndoGA values 
as outcome and the features as independent variables. 
Development and validation of scores 
We developed three EREFS-based scores (Table 1 ). For each patient, the mean of five 
EndoGA values was used as outcome. 
     Using the evaluation group data, the simple EREFS score ranging 0-8 was calculated 
(Supplementary Table 1 ). The scores were used as predictors for mean EndoGA in a linear 
regression, and the goodness of fit was assessed using R2. 
     Using the evaluation group data, we developed two scores, the weighted EREFS score 
and the weighted EREFS-proximal/distal score, by fitting the predictors to the mean EndoGA 
scores using linear regression models. We assessed goodness of fit using R2. The models’ 
coefficients were used as values for the scores, which were transformed to range 0-100 
(coefficients×100/∑all coefficients, rounded to 0.5). For weighted EREFS-proximal/distal 
score, most EREFS features were graded as described by Hirano et al.4 The presence of 
crêpe-paper and the stricture severity were also examined. We also created the binary 
variables to indicate that most severe form of a feature is present in both esophageal 
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sections. We removed non-significant predictors from the model by backward elimination 
process. We also developed weighted scores using EndoGAown as outcome. 
     To validate weighted scores (based on EndoGA or EndoGAown), we used validation group 
data. The agreement between the EndoGA/EndoGAown and the calculated score values was 
examined using the following plots: 1) Bland-Altman: (10×EndoGA-Score) versus 
(10×EndoGA+Score)/2 (the closer the horizontal line is to zero, the better is agreement 
between the measures); and 2) calibration: EndoGA/EndoGAown versus score values 
(goodness of fit evaluated using R2; for a perfect score the line fitted between 
EndoGA/EndoGAown and score values has a slope of one). For each score, we also fit a 
linear regression model with score value as predictor and EndoGAown as outcome. R2 was 
calculated and meta-analyzed using a random effects meta-analysis model (R’s “metafor” 
package). We estimated the R2 variance using the CI.Rsq function (R’s “psychometric” 
package) and calculated the standard error/confidence intervals of R2 using a large sample 
approximation.9 
Fluticasone clinical trial and scores’ responsivene ss 
A randomized, double-blind, placebo-controlled trial (Phase 1b/2a) of fluticasone (APT-1011) 
examined the tolerability and safety of two APT-1011 dosing regimens compared to placebo 
in adolescent/adult EoE patients (clinicaltrials.gov ID: NCT01386112).8 Subjects were 
randomized 1:1:1 to receive either APT-1011 1.5 mg BID (n=8), APT-1011 3.0 mg QD (n=8), 
or placebo (n=8). During EGDs at baseline and end of treatment (EOT) (week 8), EREFS 
were assessed. At EOT, the median esophageal eosinophil counts/mm2 were significantly 
decreased from baseline in biopsies of patients given APT-1011 but not placebo (379 [IQR 
289–563] to 0 [IQR 0–60] in APT-1011 1.5 mg BID, 378 [IQR 224–458] to 23 [IQR 0–109] in 
APT-1011 3.0 mg QD; and 459 [IQR 286–609] to 323 [IQR 200–523] in placebo). We 
examined scores’ change (responsiveness) from baseline to EOT in drug-treated groups 
pulled together relative to placebo using ANCOVA models with time, treatment group, and 
an interaction term as fixed effects. 
     All authors had access to the study data and reviewed and approved the final manuscript. 
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RESULTS 
The characteristics of 266 prospectively included adult EoE patients are shown in Table 2 . 
The endoscopic characteristics of patients are shown in Supplementary Table 2 . 
The relationship between EndoGA and overall severit y grading 
We explored the relationship between overall severity grading and EndoGA 
(Supplementary Figure 1 ). We observed a two-point increase in predicted EndoGA for one 
level increase in a severity grading. This increase was independent of whether a physician 
performed EGD or ranked the EREFS findings provided by another physician. This is further 
confirmed by our finding that the mean difference between EndoGAown and EndoGAothers 
values is centered around zero irrespective of the severity grading. 
Variation in endoscopic activity assessment 
When examining per-expert variation in EndoGA value distribution in the evaluation group 
(Figure 1A ), we found that experts three, four, and five have a higher number of EndoGA 
values at the lower spectrum of severity. The mean EndoGA values (±SD and range) 
provided by endoscopists were: 4.35±2.91 (0-10); 3.55±2.18 (0-9); 2.27±1.96 (0-8.54); 
3.51±2.46 (0-10); 3.44±2.50 (0-10). 
     The median ∆EndoGA for each patient’s EGD was 2.29 (IQR 1.02-3.61, range 0-6.56). 
To evaluate which endoscopic features contributed most to ∆EndoGA variation, we 
examined the univariable linear regression R2 values, which were as follows: exudates, 
R2=0.411; rings, R2=0.128; edema, R2=0.347; furrows, R2=0.299; strictures, R2=0.002; 
stricture diameter, R2=0.026, and crêpe-paper, R2=0.043. Thus, exudates, edema, and 
furrows explained a relevant part of ∆EndoGA variation. Using multivariable analyses, we 
found that except for crêpe-paper (p-value=0.634), all the other features explained a part of 
∆EndoGA variation (exudates, p-value<0.001; rings, p-value=0.003; edema, p-value<0.001; 
furrows, p-value=0.048; stricture diameter, p-value=0.03). 
     Lastly, we analyzed the variation in the way experts synthesize information about the 
presence/severity of endoscopic features by regressing each expert’s EndoGA on the 
features (Supplementary Table 3 , Figure 1B ). The experts ‘attributed’ similar weights to the 
presence of furrows, edema, and crêpe-paper. For features with more than two severity 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Schoepfer et al. Endoscopy score for adults with eosinophilic esophagitis Page 14 
levels, we observed that the more severe the feature, the greater is the variation in the 
expert-attributed weights. 
Development and validation of endoscopic scores 
Simple EREFS scores 
The median simple EREFS score in evaluation group was 3 (IQR 2–5, range 0-8). Using 
linear regression modelling in evaluation group, we found that a simple EREFS score 
explained 90.0% variation in the mean EndoGA (R2=0.900, coefficient=1.100, 95% CI 
=1.040–1.161, intercept=-0.44). The crêpe-paper addition did not improve this performance. 
The correlation between the mean EndoGA values and simple EREFS-based scores are 
shown in Supplementary Figure 2 . 
Weighted EREFS scores 
We then developed an EREFS-based score estimating the weights that expert endoscopists 
attributed to various features (Table 3 ). The variation in the severity of major endoscopic 
features explained 91.6% variation in EndoGA. The model’s coefficients were used as the 
values for the score (transformed to range 0-100). In the validation group, the weighted 
EREFS score explained 89.2% of the mean EndoGA variation (Figure 2A ). In Bland-Altman 
plot, the mean difference of -4.70 between weighted EREFS score and the mean EndoGA 
was observed (95% CI:10.46, -19.86) (Figure 2B ). The crêpe-paper addition had a small 
impact on weighted score (Figure 2C/D ). If validation was carried out using EndoGAown as 
an outcome, the weighted EREFS score explained 80.0% (meta-analyzed R2, 
Supplementary Figure 3B ) and 77.1% (Supplementary Figure 4A ) of the mean 
EndoGAown variation. In Bland-Altman analyses, the mean difference of -3.54 between 
weighted EREFS score and the mean EndoGAown was observed (95% CI: 20.74, -27.81) 
(Supplementary Figure 4B ). 
Weighted EREFS-proximal/distal score 
We developed a weighted EREFS score that considered stricture severity and presence of 
crêpe-paper. The variation in the severity of different features explained 95.9% variation in 
EndoGA (R2=0.959). Using backwards elimination, crêpe-paper and furrowing were 
removed, with only a minor change in R2 (Table 4 ). The final model’s coefficients were used 
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as the values for the score (transformed to range 0-100). In the validation group, the 
weighted EREFS-proximal/distal score estimated 94.8% of the mean EndoGA (Figure 2E ). 
In Bland-Altman plot, mean difference of 2.03 between weighted EREFS-proximal/distal 
score and the mean EndoGA was observed (95% CI: 12.12, -8.05) (Figure 2F ). If validation 
was carried out using EndoGAown as an outcome, the weighted EREFS-proximal/distal score 
explained 85% of the mean EndoGAown variation (meta-analyzed R2 in Supplementary 
Figure 3C ; Supplementary Figure 4C ). In Bland-Altman analyses, the mean difference of 
3.46 between weighted EREFS-proximal/distal score and the mean EndoGAown was 
observed (95% CI: 24.12, -17.21) (Supplementary Figure 4D ). 
     The data on development and validation of the weighted scores based on EndoGAown as 
outcome are shown in Supplementary Tables 5  and 6, and Supplementary Figure 5 . 
Scores’ Responsiveness 
The rate of baseline to EOT change in fluticasone-treated patients (n=16) (relative to 
placebo [n=8], p-value) was -24.3 (-4.6, p-value=0.052), -23.5 (-6.56, p-value=0.12), and -
23.8 (-8.44, p-value=0.11) for simple EREFS score, weighted EREFS score, and weighted 
EREFS-proximal/distal scores, respectively (Supplementary Table 4 ). We separately 
examined the effect treatment had on inflammatory and fibrotic features. The slope analysis 
detected significant treatment benefit over placebo on inflammatory features, when using 
simple but not weighted scores. 
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DISCUSSION 
As consensus on grading endoscopic severity in currently published studies is lacking, we 
evaluated three EREFS-based scores for endoscopic activity assessment in adults with EoE. 
We found that: 1) overall impression of EoE endoscopic severity differs among 
endoscopists; 2) the simple score explained the overall variation of endoscopic severity to a 
similar extent compared to the weighted scores; and 3) when evaluating scores’ 
responsiveness in a clinical trial, the weighted scores were statistically no better than the 
simple EREFS score in differentiating fluticasone- from placebo-treated patients. Hence, the 
simple score should be used in short-term clinical trials of anti-inflammatory therapies. 
Whether weighted EREFS-proximal/distal score should be used in long-term trials and 
studies remains to be elucidated. As for clinical practice, we advocate for the use of simple 
score, as the convenience of using it outweighs the modest gains in “precision” provided by 
newly-developed scores. 
     The study’s findings have important implications for endoscopic activity assessment. 
Exudates contributed most to the per-endoscopist variation in activity assessment. 
Compared to simple score, new scores put more weight on exudates and less on the 
furrows, which is consistent with symptom severity in the same population.10 We observed 
no benefit in scoring crêpe-paper, whereas inclusion of stricture diameter is of importance, 
as persons with intermediate-/high-grade strictures experience severe symptoms and 
diminished EoE-specific quality of life.10,11 Values attributed to furrows and edema should not 
be doubled, as previously suggested.7 Inclusion of variables that account for the endoscopic 
severity in both esophageal sections resulted in statistically best score. Whether assessment 
of endoscopic findings in both esophageal sections is of benefit remains to be determined. 
The weighted scores derived based on endoscopic activity assessment of the physician 
performing EGD are statistically more heterogeneous and likely to provide less consistent 
results, when compared to the scores derived based on expert group judgement. 
     The optimal approach to assessing furrows severity using EREFS system is a subject of 
much research. Hirano et al. reported that interobserver agreement for distinguishing 
between mild and severe furrows was moderate; hence, these categories were collapsed for 
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the final EREFS system.4 Nevertheless, both types of furrows severity grading have been 
previously reported. Dellon et al. graded furrows severity as absent, mild, and severe in both 
an observational study and budesonide clinical trial.6,7 In contrast, van Rhijn et al. graded 
furrows as absent/present.5 These studies also evaluated EREFS-based scores’ 
responsiveness to treatment.5-7 Given that many EoE therapies are anti-inflammatory, 
researchers increased the weight of inflammatory features. For example, Dellon et al. 
demonstrated that doubling the points attributed to exudates and edema improved the score 
responsiveness.7 
     Therefore, we developed weighted EREFS scores that incorporate expert considerations 
in a population larger than used previously (266 compared to 93, 67, and 69 patients, 
respectively).5-7 Compared to the simple score, experts weighted severe exudates more than 
in previous studies but furrows and edema similarly. Our data are similar to those on 
symptom severity, as patients with severe exudates experience worse EoE-specific quality 
of life and severe symptoms.10,11 In contrast, quality of life and symptoms of patients, in 
whom furrows and edema are present, don’t differ from those of patients lacking these 
features.9,10 We found that weighted EREFS-proximal/distal score correlates best with 
EndoGA and has the smallest mean difference and limits of agreement, but it was no better 
at detecting fluticasone treatment benefit than a simple score. 
     Endoscopists provided EndoGA by examining a datasheet containing the summary of 
endoscopic findings to prevent the ambiguities in EREFS ranking, which would preclude us 
from developing a score (like equation with two unknowns). However, experts’ EndoGA was 
strongly associated with the severity grading obtained directly after the EGD, and the 
increase in EndoGA associated with increase in the severity grading was independent of 
whether physician performed EGD or ranked the EREFS findings provided by another 
physician. 
     Our study has strengths and limitations. The data provided to the experts included all 
EREFS features, and these were used as predictors for score development; therefore, as 
expected, large part of the variance is explained by these variables. In our study, the 
stricture diameter was estimated relative to endoscope diameter. Future studies should 
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assess the stricture diameter using balloons, bougies, or the functional luminal imaging 
probe. The scores’ responsiveness was evaluated using the data from the trial, into which 
patients with relatively mild disease activity were included. We wonder, if weighed scores 
were to perform differently, if patients with more severe disease were included. 
Nevertheless, the study’s limitations are countered by strengths including a large sample 
size, inclusion of independent group for score validation, attempt to seek consensus among 
experts, and scores’ responsiveness assessment using clinical trial data. 
     In summary, we examined various scores for endoscopic activity assessment in adult EoE 
patients. The new scores were no better in detecting the fluticasone treatment benefit over 
placebo compared to a simple EREFS score. These results suggest that the simple EREFS 
score should be used in short-term, clinical trials of anti-inflammatory therapies. 
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TABLES 
Table 1:  Summary of the developed scores. 
 Simple EREFS score  Weighted EREFS score  Weighted EREFS-proximal/distal 
score  
Takes into account expert 
considerations 
No Yes Yes 
Statistical methods for score 
derivation 
Not applicable 
Linear regression with mean 
of five EndoGA values as 
outcome 
Linear regression with mean of five 
EndoGA values as outcome 
Worst endoscopic presentation 
represents overall endoscopic 
severity for that feature 
Yes Yes 
No, severity of endoscopic features is 
assessed in both proximal and distal 
esophagus by introducing extra 
variables denoting presence of 
endoscopic features in both parts of 
the esophagus 
Validation Not applicable 
Validated in second 
independent group of patients 
Validated in second independent 
group of patients 
Responsiveness 
Yes, evaluated using data 
from short-term randomized 
placebo-controlled clinical 
study of fluticasone 
Yes, evaluated using data 
from short-term randomized 
placebo-controlled clinical 
study of fluticasone 
Yes, evaluated using data from short-
term randomized placebo-controlled 
clinical study of fluticasone 
Components of the score 
Rings 
 none 
 mild 
 moderate 
 severe 
Exudates 
 none 
 mild 
Rings 
 none 
 mild 
 moderate 
 severe 
Exudates 
 none 
 mild 
Rings 
 none 
 mild in prox. and/or dist. 
 moderate in prox. and/or dist. 
 severe in prox. and/or dist. 
Exudates 
 none 
 mild in prox. and/or dist. 
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 severe 
Furrows 
 absent 
 present 
Edema 
 absent 
 present 
Strictures 
 absent 
 present 
(Crêpe paper 
 absent 
 present) 
 severe 
Furrows 
 absent 
 present 
Edema 
 absent 
 present 
Strictures 
 absent 
 present 
(Crêpe paper 
 absent 
 present) 
 severe in prox. and/or dist. 
Edema 
 absent 
 present in prox. and/or dist.. 
Crêpe-paper 
 absent 
 present in prox. and/or dist. 
Strictures 
 absent 
 low-grade in prox. and/or dist. 
 intermediate /high in prox. 
and/or dist. 
Severe rings 
 absent in prox. and dist. 
 present in prox. and dist. 
Severe exudates 
 absent in prox. and dist. 
 present in prox. and dist. 
Furrows 
 absent in prox. and dist. 
 present in prox. and dist. 
Edema 
 absent in prox. and dist. 
 present in prox. and dist. 
Abbreviations:  dist., distal part of esophagus; EREFS, edema, rings, exudates, furrows, and strictures; EndoGA, endoscopist global assessment; prox., proximal 
part of esophagus. 
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Table 2:  Patient characteristics. 
 Evaluation group Validation group 
Characteristic Frequency % Frequency % 
Number of patients 146 (100.0) 120 (100.0) 
Males 104 (71.2) 73 (60.8) 
Age at inclusion (median, interquartile range, 
range) 37.7 
(29 - 46; 
18 - 71) 
40.5 
(31 - 49; 
19 - 80) 
Ethnicity     
White 142 (97.3) 114 (95.0) 
Non-white 4 (2.7) 6 (5.0) 
Education     
Compulsory schooling 2 (1.4) 1 (0.8) 
Vocational training 36 (24.7) 33 (27.5) 
Upper secondary education 63 (43.2) 54 (45.0) 
University education 45 (30.8) 32 (26.7) 
Eosinophilic esophagitis symptoms onset     
1 to 11 months ago 8 (5.5) 2 (1.7) 
1 to 5 years ago 61 (41.8) 38 (31.7) 
more than 5 years ago 77 (52.7) 80 (66.6) 
Clinical activity (EEsAI PRO score, range 0 - 
100) 27 
(12-46;  
0-94) 
27 
(6-42;  
0-94) 
Peak esophageal eosinophil count per mm 2 
(median, interquartile range, range) 95 
(26 – 226; 
0 - 744) 
87 
(11 – 305; 
0 – 1558) 
Allergic diseases / Allergies     
Asthma 53 (36.3) 42 (35.0) 
Rhinoconjunctivitis 87 (59.6) 72 (60.0) 
Eczema 18 (12.3) 34 (28.3) 
Food allergy 43 (29.5) 60 (50.0) 
Gastro-esophageal reflux disease 45 (30.8) 18 (15.0) 
Diagnosis established:     
Clinically 26 (57.8) 3 (16.7) 
Endoscopically 11 (24.4) 6 (33.3) 
Based on pH-metric studies 1 (2.2) 2 (11.1) 
Clinically and endoscopically 8 (17.8) 5 (27.8) 
Concomitant medications     
Proton-pump inhibitors 80 (54.8) 39 (32.5) 
Histamine antagonists (H2-receptor) 5 (3.4) 1 (0.8) 
Histamine antagonists (H1-receptor) 24 (16.4) 18 (15.0) 
Inhaled corticosteroids for asthma 4 (2.7) 4 (3.3) 
β2-adrenergic agonists for asthma 21 (14.4) 2 (1.7) 
Leukotriene receptor antagonists for asthma 4 (2.7) 1 (0.8) 
EoE-specific treatments  in the last 12 months 86 (58.9) 103 (85.8) 
Hypo-allergenic diets 17 (11.6) 19 (15.8) 
Swallowed topical corticosteroids 62 (42.5) 78 (65.0) 
Esophageal dilation 27 (18.5) 26 (21.7) 
Abbreviations:  EEsAI, eosinophilic esophagitis activity index; PRO, patient-reported outcomes. 
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Table 3:  Multivariable linear regression model for derivation of weighted EREFS scores (with and without crêpe-paper). Final scores. 
 Coefficient a 95% CI P-value Score (total set to 100) Coefficient
a 95% CI P-value Score (total set to 100) 
Rings 
 none 
 mild 
 moderate 
 severe 
 
0.000 
1.239 
2.169 
3.332 
 
Ref. 
0.941 – 1.538 
1.807 – 2.531 
2.773 – 3.890 
 
 
<0.001 
<0.001 
<0.001 
 
0 
13 
23 
35.5 
 
0.000 
1.223 
2.132 
3.216 
 
Ref. 
0.937 – 1.510 
1.784 – 2.480 
2.677 – 3.756 
 
 
<0.001 
<0.001 
<0.001 
 
0 
12.5 
22 
33.5 
Exudates 
 none 
 mild 
 severe 
 
0.000 
1.341 
3.155 
 
Ref. 
1.058 – 1.624 
2.685 – 3.625 
 
 
<0.001 
<0.001 
 
0 
14 
33.5 
 
0.000 
1.373 
3.082 
 
Ref. 
1.101 – 1.645 
2.629 – 3.534 
 
 
<0.001 
<0.001 
 
0 
14 
32 
Furrows 
 absent 
 present 
 
0.000 
0.586 
 
Ref. 
0.277 – 0.896 
 
 
<0.001 
 
0 
6 
 
0.000 
0.608 
 
Ref. 
0.311 – 0.906 
 
 
<0.001 
 
0 
6.5 
Edema 
 absent 
 present 
 
0.000 
1.232 
 
Ref. 
0.939 – 1.524 
 
 
<0.001 
 
0 
13 
 
0.000 
1.128 
 
Ref. 
0.841 – 1.414 
 
 
<0.001 
 
0 
11.5 
Strictures 
 absent 
 present 
 
0.000 
1.117 
 
Ref. 
0.822 – 1.411 
 
 
<0.001 
 
0 
12 
 
0.000 
0.965 
 
Ref. 
0.671 – 1.260 
 
 
<0.001 
 
0 
10 
Crêpe-paper 
 absent 
 present 
NA NA NA NA  
0.000 
0.652 
 
Ref. 
0.292 – 1.013 
 
 
<0.001 
 
0 
6.5 
Constant b 0.044 -0.201 – 0.289 0.722  0.078 -0.158 – 0.314 0.514  
R2c 0.916    0.923    
Sum of the 
coefficients/
Score 
9.422   100 9.651   100 
 
Abbreviations:  CI, confidence interval; EndoGA, endoscopist global assessment; Ref. reference. 
a The coefficient represents the EndoGA value change for each endoscopic feature. For example, mean EndoGA increased by 1.239, if mild rings were found. In these analyses, the 
adjusted regression coefficient for rings represents the amount of mean EndoGA variation that is owing to the rings alone, after the presence of all other features was considered. If 
mild rings and edema were detected, then mean EndoGA increased by 2.471 (1.239 for mild rings and 1.232 for edema). 
b The constant represents the predicted EndoGA value, when all values of independent variables are set to reference category. 
c R2 is a measure of the extent to which the regression model describes the data. The closer R2 is to one, the more precise the regression model is. 
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Table 4:  Multivariable linear regression model for derivation of the weighted EREFS-proximal/distal score. Model 1 includes all predictors, whilst 
models 2 and 3 are fitted to the data after exclusion of the least significant features. Final score. 
 Model 1  Model 2   Model 3  Score  
 Coeff a 95% CI P-value Coeff
a 95% CI P-value Coeff
a 95% CI P-value 
(total set to 
100) 
Rings 
 none 
 mild in prox. and/or dist. 
 moderate in prox. and/or dist. 
 severe in prox. and/or dist. 
 
0.000 
1.018 
1.871 
1.703 
 
Ref. 
0.796 – 1.241 
1.605 – 2.136 
1.043 – 2.362 
 
<0.001 
 
0.000 
1.018 
1.871 
1.678 
 
Ref. 
0.796 – 1.240 
1.607 – 2.136 
1.034 – 2.322 
 
<0.001 
 
0.000 
1.022 
1.875 
1.677 
 
Ref. 
0.801 – 1.242 
1.612 – 2.138 
1.034 – 2.319 
 
<0.001 
 
0 
10 
18 
18 
Exudates 
 none 
 mild in prox. and/or dist. 
 severe in prox. and/or dist. 
 
0.000 
1.525 
2.021 
 
Ref. 
1.316 – 1.734 
1.402  – 2.639 
 
<0.001 
 
0.000 
1.524 
2.042 
 
Ref. 
1.316 – 1.732 
1.436  – 2.648 
 
<0.001 
 
0.000 
1.537 
2.055 
 
Ref. 
1.337 – 1.738 
1.453 – 2.657 
 
<0.001 
 
0 
15 
19.5 
Furrows 
 absent 
 present in prox. and/or dist. 
 
0.000 
0.082 
 
Ref. 
-0.278 – 0.441 
 
0.653 
 
0.000 
0.087 
 
Ref. 
-0.271 – 0.444 
 
0.633 
- - - - 
Edema 
 absent 
 present in prox. and/or dist.. 
 
0.000 
0.475 
 
Ref. 
0.005 – 0.944 
 
0.048 
 
0.000 
0.464 
 
Ref. 
0.000 – 0.929 
 
0.050 
 
0.000 
0.526 
 
Ref. 
0.136 – 0.915 
 
0.009 
 
0 
5 
Crêpe-paper 
 absent 
 present in prox. and/or dist. 
 
0.000 
0.471 
 
Ref. 
0.011 – 0.931 
 
0.045 
 
0.000 
0.540 
 
Ref. 
0.254 – 0.826 
 
<0.001 
 
0.000 
0.534 
 
Ref. 
0.250 – 0.818 
 
<0.001 
 
0 
5 
Strictures 
 absent 
 low-grade in prox. and/or dist. 
 intermediate /high in prox. and/or dist. 
 
0.000 
0.836 
1.875 
 
Ref. 
0.612 – 1.060 
1.426 – 2.324 
 
<0.001 
 
0.000 
0.835 
1.872 
 
Ref. 
0.612 – 1.058 
1.425 – 2.319 
 
<0.001 
 
0.000 
0.836 
1.866 
 
Ref. 
0.613 – 1.058 
1.421 – 2.311 
 
<0.001 
 
0 
8 
18 
Severe rings 
 absent in prox. and dist. 
 present in prox. and dist. 
 
0.000 
0.776 
 
Ref. 
0.141 – 1.410 
 
0.017 
 
0.000 
0.795 
 
Ref. 
0.170 – 1.419 
 
0.013 
 
0.000 
0.808 
 
Ref. 
0.188 – 1.429 
 
0.011 
 
0 
8 
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 Model 1  Model 2   Model 3  Score  
 Coeff a 95% CI P-value Coeff
a 95% CI P-value Coeff
a 95% CI P-value 
(total set to 
100) 
Severe exudates 
 absent in prox. and dist. 
 present in prox. and dist. 
 
0.000 
1.377 
 
Ref. 
0.650 – 2.104 
 
<0.001 
 
0.000 
1.342 
 
Ref. 
0.641 – 2.043 
 
<0.001 
 
0.000 
1.333 
 
Ref. 
0.635 – 2.031 
 
<0.001 
 
0 
13 
Furrows 
 absent in prox. and dist. 
 present in prox. and dist. 
 
0.000 
0.893 
 
Ref. 
0.539 – 1.248 
 
<0.001 
 
0.000 
0.891 
 
Ref. 
0.538 – 1.244 
 
<0.001 
 
0.000 
0.958 
 
Ref. 
0.735 – 1.181 
 
<0.001 
 
0 
9 
Edema 
 absent in prox. and dist. 
 present in prox. and dist. 
 
0.000 
0.508 
 
Ref. 
0.025 – 0.990 
 
0.039 
 
0.000 
0.522 
 
Ref. 
0.047 – 0.997 
 
0.031 
 
0.000 
0.465 
 
Ref. 
0.055 – 0.875 
 
0.027 
 
0 
4.5 
Crêpe-paper 
 absent in prox. and dist. 
 present in prox. and dist. 
 
0.000 
0.101 
 
Ref. 
-0.429 – 0.630 
 
0.707 
 
- - - - - - - 
Constant 0.193 0.131 – 0.374 0.036 0.192 0.122 – 0.371 0.037 0.201 0.027 – 0.376 0.024 - 
R2 0.959   0.959   0.958    
Sum       10.419   100 
Abbreviations:  Coeff, coefficient; CI, confidence interval; dist., distal; EndoGA, endoscopist global assessment; prox., proximal; Ref. reference. 
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FIGURES 
Figure 1:  A. The distribution of global assessment values provided by endoscopists. The 
vertical lines indicate the interquartile range; the crossing horizontal line is at the median. 
Rhombi indicate the mean. B. Variation in the weights that five endoscopists attribute to 
different endoscopic features. 
Figure 2:  The calibration plots for (A) weighted EREFS, (C) weighted EREFS with crêpe-
paper (EREFSC), and (E) weighted EREFS-proximal/distal (EREFS-PD) scores in the 
validation group. The solid line has a slope of one and represents an ideal relationship 
between a perfect score and EndoGA values. The dashed line is the regression line fit to the 
data. Bland–Altman plots for the agreement between (B) weighted EREFS, (D) weighted 
EREFSC, (F) weighted EREFS-PD scores and 10×EndoGA in the validation group. The grey 
box indicates the 95% confidence intervals limits of agreement. 
Supplementary Figure 1:  The relationship between EndoGA and overall severity grading: 
A. Relationship between fixed portion of estimated EndoGA and overall severity grading. 
The vertical lines indicate the 95% confidence interval. The box-and-whiskers plots of (B) 
mean difference between EndoGA for EGD performed in one’s own center (EndoGAown) and 
EndoGA for EGD performed in another center (EndoGAothers), (C) EndoGAown, (D) 
EndoGAothers versus overall severity grading. 
Supplementary Figure 2:  The correlation between the simple EREFS scores and EndoGA 
without the crêpe-paper (A) and with crêpe-paper (B) in the evaluation group. 
Supplementary Figure 3:  The meta-analyzed R2 values for (A) simple EREFS score, (B) 
weighted EREFS score, and (C) weighted EREFS-proximal/distal score. 
Supplementary Figure 4:  The calibration plots of EndoGAown versus the weighted scores in 
the validation group: (A) weighted EREFS score, (C) weighted EREFS-proximal/distal 
(EREFS-PD) score. The solid line has a slope of one and represents an ideal relationship 
between a perfect score and EndoGA values. The dashed line is the regression line fit to the 
data. The Bland–Altman plots for the agreement between the weighted scores and 
10×EndoGA in the validation group: (B) weighted EREFS score, (D) weighted EREFS-PD 
score. The grey box indicates the 95% confidence intervals limits of agreement. 
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Supplementary Figure 5:  The calibration plots of EndoGAown versus for the weighted 
scores developed based on EndoGAown in the validation group: (A) weighted EREFS score, 
(C) weighted EREFS-proximal/distal (EREFS-PD) score. The solid line has a slope of one 
and represents an ideal relationship between a perfect score and EndoGA values. The 
dashed line is the regression line fit to the data. The Bland–Altman plots for the agreement 
between the weighted scores and 10×EndoGA in the validation group: (B) weighted EREFS 
score, (D) weighted EREFS-PD score. The grey box indicates the 95% confidence intervals 
limits of agreement. 
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SUPPLEMENTARY TABLES 
Supplementary Table 1:  The EREFS classification and grading system-based score. In 
addition to absence/presence of strictures, we evaluated whether low-grade, intermediate-
grade, or high-grade stricture(s) were found. 
Feature  Grading  Definition  Points 
Major features  
Rings 
(< 1 cm 
length)  
Grade 0 
Grade 1 
Grade 2 
 
 
Grade 3 
None 
Mild (subtle circumferential ridges) 
Moderate (distinct rings that do not impair passage of 
a standard diagnostic adult endoscope [outer diameter 
8-10 mm]) 
Severe (distinct rings that do not permit passage of a 
diagnostic endoscope) 
0 
1 
2 
 
 
3 
Exudates Grade 0 
Grade 1 
 
Grade 2 
None 
Mild (lesions involving <10% of the esophageal 
surface area) 
Severe (lesions involving >10% of the esophageal 
surface area) 
0 
1 
 
2 
Furrows  Grade 0 
Grade 1 
Absent 
Present 
0 
1 
Edema Grade 0 
Grade 1 
Absent (distinct vascularity present) 
Loss of clarity or absence of vascular markings 
0 
1 
Stricture  
(≥ 1 cm 
length) 
Grade 0 
Grade 1 
OR 
Grade 0 
Grade 1 
 
 
Grade 2 
 
 
 
Grade 3 
Absent 
Present 
OR 
None 
Low-grade (esophageal diameter 11-13 mm, passage 
of standard endoscope possible against mild 
resistance) 
Intermediate-grade (esophageal diameter 7-10 mm, 
passage of a 6-mm outer diameter endoscope 
possible, but impossible with standard endoscope [8-
10-mm outer diameter]) 
High-grade (passage of a 6-mm outer diameter 
endoscope is not possible) 
0 
1 
 
NA 
NA 
 
NA 
 
 
NA 
 
NA 
Total score  8 
Minor feature  
Crêpe-
paper 
Grade 0 
Grade 1 
Absent 
Present 
0 
1 
Total score including crêpe paper 9 
Abbreviations:  NA, not applicable.
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Supplementary Table 2:  Endoscopic findings in proximal and distal esophagus as well as in 
esophagus ‘overall’ in all patients, evaluation and validation groups. 
Characteristic  Proximal   Distal   Overall   
 Frequency  % Frequency  % Frequency  % 
Endoscopic findings (n=266)       
Rings: Absent 104 39.1 81 30.5 74 27.8 
Mild 89 33.5 99 37.2 99 37.2 
Moderate 58 21.8 73 27.4 77 28.9 
Severe 12 4.5 12 4.5 16 6.0 
Missing 3 1.1 1 0.4 0 0.0 
Strictures: Absent 223 83.8 192 72.2 178 66.9 
Present 40 15.0 73 27.4 88 33.1 
Missing 3 1.1 1 0.4 0 0.0 
Exudates: Absent 205 77.1 183 68.8 177 66.5 
Mild 46 17.3 67 25.2 73 27.4 
Severe 14 5.3 14 5.3 16 6.0 
Missing 1 0.4 2 0.8 0 0.0 
Furrows: Absent 137 51.5 105 39.5 102 38.3 
Present 128 48.1 160 60.2 164 61.7 
Missing 1 0.4 1 0.4 0 0.0 
Edema: Absent 140 52.6 114 42.9 113 42.5 
Present 125 47.0 151 56.8 153 57.5 
Missing 1 0.4 1 0.4 0 0.0 
Crêpe-paper:  Absent 239 89.8 239 89.8 234 88.0 
Present 26 9.8 26 9.8 32 12.0 
Missing 1 0.4 1 0.4 0 0.0 
Endoscopic findings (evaluation 
group, n=146) 
      
Rings: Absent 54 37.0 44 30.1 39 26.7 
Mild 46 31.5 54 37.0 53 36.3 
Moderate 36 24.7 40 27.4 44 30.1 
Severe 8 5.5 7 4.8 10 6.8 
Missing 2 1.4 1 0.7 0 0.0 
Strictures: Absent 117 80.1 104 71.2 96 65.8 
Present 27 18.5 41 28.1 50 34.2 
Missing 2 1.4 1 0.7 0 0.0 
Exudates: Absent 108 74.0 100 68.5 97 66.4 
Mild 28 19.2 36 24.7 39 26.7 
Severe 9 6.2 8 5.5 10 6.8 
Missing 1 0.7 2 1.4 0 0.0 
Furrows: Absent 62 42.5 50 34.2 49 33.6 
Present 83 56.8 95 65.1 97 66.4 
Missing 1 0.7 1 0.7 0 0.0 
Edema: Absent 67 45.9 61 41.8 61 41.8 
Present 78 53.4 84 57.5 85 58.2 
Missing 1 0.7 1 0.7 0 0.0 
Crêpe-paper:  Absent 129 88.4 129 88.4 127 87.0 
Present 16 11.0 16 11.0 19 13.0 
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Missing 1 0.7 1 0.7 0 0.0 
Endoscopic findings (validation 
group, n=120)  
      
Fixed rings: Absent 50 41.7 38 31.7 35 29.2 
Mild 43 35.8 44 36.7 46 38.3 
Moderate 22 18.3 33 27.5 33 27.5 
Severe 4 3.3 5 4.2 6 5.0 
Missing 1 0.8 0 0.0 0 0.0 
Strictures: Absent 97 80.8 82 68.3 80 66.7 
Present 18 15.0 32 26.7 34 28.3 
Missing 5 4.2 6 5.0 6 5.0 
Exudates: Absent 0 0.0 0 0.0 0 0.0 
Mild 106 88.3 86 71.7 82 68.3 
Severe 13 10.8 34 28.3 38 31.7 
Missing 1 0.8 0 0.0 0 0.0 
Furrows: Absent 75 62.5 55 45.8 53 44.2 
Present 45 37.5 65 54.2 67 55.8 
Missing 0 0.0 0 0.0 0 0.0 
Edema: Absent 73 60.8 53 44.2 52 43.3 
Present 47 39.2 67 55.8 68 56.7 
Missing 0 0.0 0 0.0 0 0.0 
Crêpe-paper:  Absent 110 91.7 110 91.7 107 89.2 
Present 10 8.3 10 8.3 13 10.8 
Missing 0 0.0 0 0.0 0 0.0 
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Supplementary Table 3:  Multivariable linear regression model with endoscopist global assessment as an outcome and endoscopic features 
(dependent variables) – one for each expert endoscopist. 
 Expert 1 Expert 2 Expert 3 Expert 4 Expert 5 
 Coeff 95% CI P Coeff 95% CI P Coeff 95% CI P Coeff 95% CI P Coeff 95% CI P 
Rings 
 none 
 mild 
 moderate 
 severe 
 
0.000 
1.219 
3.049 
3.672 
 
Ref. 
0.773 – 1.664 
2.516 – 3.583 
2.600 – 4.743 
 
 
<0.001 
<0.001 
<0.001 
 
0.000 
1.917 
2.755 
3.147 
 
Ref. 
1.575 – 2.259 
2.345 – 3.164 
2.325 – 3.969 
 
 
<0.001 
<0.001 
<0.001 
 
0.000 
0.879 
1.683 
2.694 
 
Ref. 
0.596 – 1.162 
1.344 – 2.023 
2.013 – 3.375 
 
 
<0.001 
<0.001 
<0.001 
 
0.000 
1.083 
1.614 
1.883 
 
Ref. 
0.693 – 1.474 
1.146 – 2.082 
0.943 – 2.822 
 
 
<0.001 
<0.001 
<0.001 
 
0.000 
1.113 
1.576 
1.722 
 
Ref. 
0.697 – 1.529 
1.077 – 2.075 
0.721 – 2.723 
 
 
<0.001 
<0.001 
<0.001 
Strictures 
 absent 
 low-grade 
 intermedi
ate /high 
 
0.000 
0.532 
1.302 
 
Ref. 
0.069 – 0.994 
0.395 – 2.208 
 
 
0.025 
0.005 
 
0.000 
0.625 
0.962 
 
Ref. 
0.271 – 0.980 
0.267 – 1.658 
 
 
0.001 
0.007 
 
0.000 
1.578 
3.064 
 
Ref. 
1.284 – 1.872 
2.487 – 3.640 
 
 
<0.001 
<0.001 
 
0.000 
0.749 
1.975 
 
Ref. 
0.347 – 1.151 
1.180 – 2.770 
 
 
<0.001 
<0.001 
 
0.000 
0.591 
0.875 
 
Ref. 
0.163 – 1.020 
0.028 – 1.721 
 
 
0.007 
0.043 
Exudates 
 none 
 mild 
 severe 
 
0.000 
1.593 
3.586 
 
Ref. 
1.171 – 2.015 
2.885 – 4.288 
 
 
<0.001 
<0.001 
 
0.000 
0.479 
2.470 
 
Ref. 
0.155 – 0.803 
1.932 – 3.008 
 
 
0.004 
<0.001 
 
0.000 
0.295 
0.638 
 
Ref. 
0.027 – 0.563 
0.191 – 1.084 
 
 
0.031 
0.005 
 
0.000 
2.097 
3.947 
 
Ref. 
1.729 – 2.466 
3.332 – 4.562 
 
 
<0.001 
<0.001 
 
0.000 
2.284 
4.410 
 
Ref. 
1.892 – 2.676 
3.754 – 5.065 
 
 
<0.001 
<0.001 
Furrows 
 absent 
 present 
 
0.000 
0.878 
 
Ref. 
0.413 – 1.344 
 
 
<0.001 
 
0.000 
1.100 
 
Ref. 
0.741 – 1.455 
 
 
<0.001 
 
0.000 
0.511 
 
Ref. 
0.215 – 0.807 
 
 
0.001 
 
0.000 
0.556 
 
Ref. 
0.148 – 0.964 
 
 
0.008 
 
0.000 
0.515 
 
Ref. 
0.080 – 0.949 
 
 
0.021 
Edema 
 absent 
 present 
 
0.000 
1.607 
 
Ref. 
1.164 – 2.050 
 
 
<0.001 
 
0.000 
1.021 
 
Ref. 
0.681 – 1.361 
 
 
<0.001 
 
0.000 
0.319 
 
Ref. 
0.037 – 0.601 
 
 
0.027 
 
0.000 
1.165 
 
Ref. 
0.776 – 1.553 
 
 
<0.001 
 
0.000 
1.287 
 
Ref. 
0.873 – 1.701 
 
 
<0.001 
Crêpe-paper 
 absent 
 present 
 
0.000 
0.789 
 
Ref. 
0.212 – 1.366 
 
 
0.008 
 
0.000 
-0.502 
 
Ref. 
-0.493 – 0.392 
 
 
0.823 
 
0.000 
0.352 
 
Ref. 
-0.014 – 0.720 
 
 
0.059 
 
0.000 
0.701 
 
Ref. 
0.196 – 1.205 
 
 
0.007 
 
0.000 
0.930 
 
Ref. 
0.393 – 1.468 
 
 
0.001 
Constant 0.209 -0.157 – 0.574 0.261 -0.037 -0.317 – 0.244 0.796 -0.111 -0.343 – 0.122 0.348 0.147 -0.174 – 0.467 0.367 0.086 -0.256 – 0.427 0.621 
R2 0.890   0.885   0.902   0.882   0.870   
Abbreviations:  CI, confidence interval; Ref. reference. 
The constant represents the predicted EndoGA value, when all values of independent variables are set to reference category. 
R2 is a measure of the extent to which the regression model describes the observed data. The closer R2 is to one, the more precise the regression 
model is. 
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Supplementary Table 4:  Responsiveness of the developed scores. 
 
Baseline to end of 
treatment slope of 
change in drug-
treated group 
(converted from 0 to 
100 for simple score)  
Baseline to end of 
treatment slope of 
change in placebo 
group-treated group 
(converted from 0 to 
100 for simple score) 
p-
value 
Simple EREFS total score -1.94 (-24.3) -0.37 (-4.6) 0.052 
Simple EREFS inflammatory* -1.62 (-20.3) -0.37 (-4.6) 0.04 
Simple EREFS fibrotic* -0.31 (3.9) 0.00 (0.0) 0.62 
Weighted EREFS total score -23.5 -6.6 0.12 
Weighted EREFS inflammatory* -19.9 -6.9 0.13 
Weighted EREFS fibrotic* -3.6 0.4 0.59 
Weighted EREFS-
proximal/distal score total 
score -23.8 -8.4 0.11 
EREFS-proximal/distal score 
inflammatory* -20.8 -10.6 0.17 
Weighted EREFS-
proximal/distal score fibrotic* -3.1 2.1 0.39 
* In addition to the overall EREFS-based scores, we also separately examined the treatment effect on inflammatory 
endoscopic features (exudates, furrows, and edema) and fibrotic endoscopic features (rings, strictures, [and crêpe-
paper for EREFS-proximal/distal score]). 
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Supplementary Table 5:  Weighted EREFS scores based on average of five values of EndoGA and single 
EndoGAown values. 
 
Weighted EREFS score 
based on average of 5 values 
of EndoGA (total set to 100) 
New weighted EREFS 
score based on EndoGA own 
(total set to 100) 
Rings 
 none 
 mild 
 moderate 
 severe 
 
0 
13 
23 
35.5 
 
0 
12 
19 
33.5 
Exudates 
 none 
 mild 
 severe 
 
0 
14 
33.5 
 
0 
18 
38 
Furrows 
 absent 
 present 
 
0 
6 
 
0 
6 
Edema 
 absent 
 present 
 
0 
13 
 
0 
11 
Strictures 
 absent 
 present 
 
0 
12 
 
0 
11.5 
Sum of the score 100 100 
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Supplementary Table 6:  Weighted EREFS-proximal/distal scores based on average EndoGA and single EndoGAown 
values. 
 
Based on average value 
of 5 EndoGA values 
Score  
New based on 
EndoGA own   
Score  
 (total set to 100)  (total set to 100)  
Rings 
 none 
 mild in prox. and/or dist. 
 moderate in prox. and/or dist. 
 severe in prox. and/or dist. 
 
0 
10 
18 
18 
 
0 
8 
13.5 
24 
Exudates 
 none 
 mild in prox. and/or dist. 
 severe in prox. and/or dist. 
 
0 
15 
19.5 
 
0 
18.5 
24.5 
Furrows 
 absent 
 present in prox. and/or dist. 
- - 
Edema 
 absent 
 present in prox. and/or dist. 
 
0 
5 
- 
Crêpe-paper 
 absent 
 present in prox. and/or dist. 
 
0 
5 
 
0 
6.5 
Strictures 
 absent 
 low-grade in prox. and/or dist. 
 intermediate /high in prox. and/or 
dist. 
 
0 
8 
18 
 
0 
7.5 
14.5 
Severe rings 
 absent in prox. and dist. 
 present in prox. and dist. 
 
0 
8 
 
0 
-12 
Severe exudates 
 absent in prox. and dist. 
 present in prox. and dist. 
 
0 
13 
 
0 
13.5 
Furrows 
 absent in prox. and dist. 
 present in prox. and dist. 
 
0 
9 
 
0 
9.5 
Edema 
 absent in prox. and dist. 
 present in prox. and dist. 
 
0 
4.5 
 
0 
7.5 
Crêpe-paper 
 absent in prox. and dist. 
 present in prox. and dist. 
- - 
Sum of the score 100 100 
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WHAT YOU NEED TO KNOW 
BACKGROUND 
In eosinophilic esophagitis, endoscopic activity is graded by examining the presence 
and severity of Edema, Rings, Exudates, Furrows, and Strictures (EREFS). As there 
is paucity of data, we examined variation in the way experts assessed endoscopic 
severity, developed and validated three EREFS-based scores, and evaluated the 
scores’ responsiveness in clinical trial of fluticasone. 
NEW FINDINGS 
The endoscopic severity impression differs among expert endoscopists. Exudates 
accounted for most variation in severity assessment. The responsiveness of new 
scores considering expert opinion was no better than that of simple score (features 
given arbitrary values from 0-3), when clinical trial data were analyzed. 
IMPLICATIONS FOR PATIENT CARE 
The simple EREFS score should be used in short-term clinical trials of anti-
inflammatory therapies. The new score should be examined in long-term, 
observational studies of patients with broader endoscopic severity spectrum. 
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